GemVax&KAELLtd Management
Management criteria checks 0/4
We currently do not have sufficient information about the CEO.
Key information
Sang-Jae Kim
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | no data |
| CEO ownership | 3.0% |
| Management average tenure | no data |
| Board average tenure | no data |
Recent management updates
Recent updates
Some Confidence Is Lacking In GemVax&KAEL Co.,Ltd. (KOSDAQ:082270) As Shares Slide 28%
Nov 04
GemVax&KAEL Co.,Ltd.'s (KOSDAQ:082270) 30% Share Price Surge Not Quite Adding Up
Sep 19Risks To Shareholder Returns Are Elevated At These Prices For GemVax&KAEL Co.,Ltd. (KOSDAQ:082270)
Jul 05GemVax&KAELLtd's (KOSDAQ:082270) Earnings Are Weaker Than They Seem
Apr 03Is GemVax&KAELLtd (KOSDAQ:082270) A Risky Investment?
Feb 17Investors Who Bought GemVax&KAELLtd (KOSDAQ:082270) Shares Three Years Ago Are Now Up 52%
Dec 26
CEO
Sang-Jae Kim (58 yo)
no data
Tenure
Mr. Sang-Jae Kim serves as Chief Executive Officer at GemVax&KAEL Co.,Ltd. He serves as Co-Chief Executive Officer of BIOVILL Co.,Ltd. (formerly known as KSCB Co.,Ltd.) Mr. Kim serves as the Chief Executiv...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/06 00:03 |
| End of Day Share Price | 2025/01/06 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
GemVax&KAEL Co.,Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|